Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy.

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Research Pub Date : 2025-08-21 DOI:10.1186/s13550-025-01305-8

Felix L Herr, Christian Dascalescu, Victoria Fusch, Caroline Smith, Ricarda Ebner, Mathias J Zacherl, Florian Eckenweber, Konrad Klimek, Christoph J Auernhammer, Christine Spitzweg, Jens Ricke, Maurice M Heimer, Clemens C Cyran, Rudolf A Werner, Gabriel T Sheikh

引用次数: 0

Abstract Image

查看原文本刊更多论文

胃肠胰神经内分泌肿瘤患者接受Lu-DOTA-TATE治疗后肾功能下降的预测因素[177Lu]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.